

**FORM 6-K**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Report of Foreign Private Issuer**

Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934  
for the month of December 2006

Compugen Ltd.  
(Translation of registrant's name in English)

72 Pinchas Rosen Street, Tel-Aviv 69512, Israel  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover  
Form 20-F or Form 40-F.

Form 20-F X      Form 40-F \_\_\_\_

On December 12, 2006 Compugen Ltd. (the "Registrant") issued a Press Release, filed as  
Exhibit 1 to this Report on Form 6-K, which is hereby incorporated by reference herein.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has  
duly caused this report to be signed on its behalf by the undersigned, thereunto duly  
authorized.

Compugen Ltd.  
(Registrant)  
By: /s/ Nurit Benjamini  
Title: Chief Financial Officer  
Date: December 12, 2006

## **Exhibit 1**



### **Compugen to Participate in Diagnostics Panel at RBC Capital Markets 2006 Healthcare Conference**

Tel Aviv, Israel - December 12, 2006 - Compugen Ltd. (Nasdaq:CGEN) announced today that Eli Zangvil, MD, Vice President Business Development, will participate in a panel discussion at the RBC Capital Markets Healthcare Conference, at the Westin New York at Times Square in New York City. The "Diagnostics: From Discovery to Point-Of-Care" panel discussion will begin at 2:00 p.m. EST on Thursday, December 14, 2006.

A live webcast of the panel discussion will be available on Compugen's Website and at <http://www.wsw.com/webcast/rbc62/panel32>, and a replay will be available for 30 days following the presentation.

#### **About Compugen**

Compugen's mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry. The Company's powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company's decade-long pioneering efforts in the deeper understanding of important biological phenomena at the molecular level through the incorporation of ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine. To date, Compugen's product discovery efforts and its initial discovery engines have focused mainly within the areas of cancer, immune-related and cardiovascular diseases. The Company's primary commercialization pathway for its therapeutic and diagnostic product candidates is to enter into milestone and revenue sharing out-licensing and joint development agreements with leading companies. Compugen has established an agricultural biotechnology affiliate – Evogene, and a small-molecule drug discovery affiliate – Keddem Bioscience. For additional information, please visit Compugen's corporate Website at [www.cgen.com](http://www.cgen.com).

#### ***Company contact:***

Tsipi Haitovsky  
Director, Corporate Communication  
Compugen Ltd.  
Email: [tsipi@cgen.com](mailto:tsipi@cgen.com)  
Tel: +972-52-5989892